BMC infectious diseases · 2025
Coinfection with SARS-CoV-2 among patients with Streptococcus pneumoniae in Casablanca.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Katfy Mostafa, Kettani Assiya El, Katfy Khalid, Diawara Idrissa, Nzoyikorera Nehemie, Boussetta Soufiane, Abdallaoui Maha Soussi, Bousfiha Ahmed Aziz
Аннотация
BACKGROUND: During the COVID-19 pandemic caused by SARS-CoV-2, coinfections with Streptococcus pneumoniae have emerged as a significant public health concern. The impact of these coinfections on disease severity and mortality rates remains underexplored. This study aims to address this gap by analyzing the clinical outcomes of patients coinfected with S. pneumoniae and SARS-CoV-2 at CHU Ibn Rochd in Casablanca, Morocco, between 2020 and 2022.
METHODS: A cohort of 120 hospitalized patients diagnosed with S. pneumoniae infection was studied retrospectively and prospectively. Clinical and demographic data, vaccination status, and infection characteristics were collected. Among these patients, 41 were identified as coinfected with both pathogens. Statistical analyses, including multivariate logistic regression, were performed to assess associations between coinfection and clinical outcomes, such as ICU admission and mortality.
RESULTS: Compared to non-coinfected patients, those coinfected with SARS-CoV-2 had higher ICU admission (53.7% vs. 24.05%) and mortality (39.02% vs. 13.9%) rates. Multivariate analysis identified coinfection and increasing age as independent predictors of severe outcomes. The most frequent pneumococcal serotypes were 3, 19 A, 6 B, and 9 V, with 31.7% of cases involving non-vaccine types. Most coinfected patients, especially those who died, were unvaccinated against pneumococcus or SARS-CoV-2.
CONCLUSIONS: Coinfection with SARS-CoV-2 significantly increases the risk of severe outcomes in patients with S. pneumoniae infection. These findings highlight the importance of early detection and support the implementation of comprehensive vaccination strategies targeting high-risk populations.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: A cohort of 120 hospitalized patients diagnosed with S. pneumoniae infection was studied retrospectively and prospectively. Clinical and demographic data, vaccination status, and infection characteristics were collected. Among these patients, 41 were identified as coinfected with both pathogens. Statistical analyses, including multivariate logistic regression, were performed to assess associations between coinfection and clinical outcomes, such as ICU admission and mortality.
RESULTS: Compared to non-coinfected patients, those coinfected with SARS-CoV-2 had higher ICU admission (53.7% vs. 24.05%) and mortality (39.02% vs. 13.9%) rates. Multivariate analysis identified coinfection and increasing age as independent predictors of severe outcomes. The most frequent pneumococcal serotypes were 3, 19 A, 6 B, and 9 V, with 31.7% of cases involving non-vaccine types. Most coinfected patients, especially those who died, were unvaccinated against pneumococcus or SARS-CoV-2.
CONCLUSIONS: Coinfection with SARS-CoV-2 significantly increases the risk of severe outcomes in patients with S. pneumoniae infection. These findings highlight the importance of early detection and support the implementation of comprehensive vaccination strategies targeting high-risk populations.
CLINICAL TRIAL NUMBER: Not applicable.